Daniel Souery

Daniel Souery

Auto-generated profile, based on publicly available information

Daniel Souery

Laboratoire de Psychologie Medicale, Centre Européen de Psychologie Medicale, Université Libre de Bruxelles and Psy Pluriel, Brussels, Belgium

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2019 in The World Journal of Biological Psychiatry
Verified
Journal Article
Closed access
Lucie BartovaLucie Bartova
Lucie Bartova
MDMarkus Dold
Markus Dold
Alexander KautzkyAlexander Kautzky
Alexander Kautzky
CFChiara Fabbri
Chiara Fabbri
MSMarie Spies
Marie Spies
SKSiegfried Kasper
Siegfried Kasper
Objectives: The overview outlines two decades of research from the European Group for the Study of Resistant Depression (GSRD) that fundamentally impacted evidence-based algorithms for diagnostics and psychopharmacotherapy of treatment-resistant depression (TRD). Methods: The GSRD staging model characterising response, non-response and resistance to antidepressant (AD) treatment was applied to 2762 patients in eight European countries. Results: In case of non-response, dose escalation and switching between different AD classes did not show superiority over continuation of original AD treatment. Predictors for TRD were symptom severity, duration of the current major depressive episode (MDE), suicidality, psychotic and melancholic features, comorbid anxiety and personality disorders, add-on treatment, non-response to the first AD, adverse effects, high occupational level, recurrent disease course, previous hospitalisations, positive family history of MDD, early age of onset and novel associations of single nucleoid polymorphisms (SNPs) within the PPP3CC, ST8SIA2, CHL1, GAP43 and ITGB3 genes and gene pathways associated with neuroplasticity, intracellular signalling and chromatin silencing. A prediction model reaching accuracy of above 0.7 highlighted symptom severity, suicidality, comorbid anxiety and lifetime MDEs as the most informative predictors for TRD. Applying machine-learning algorithms, a signature of three SNPs of the BDNF, PPP3CC and HTR2A genes and lacking melancholia predicted treatment response. Conclusions: The GSRD findings offer a unique and balanced perspective on TRD representing foundation for further research elaborating on specific clinical and genetic hypotheses and treatment strategies within appropriate study-designs, especially interaction-based models and randomized controlled trials.

12 November 2020 in The World Journal of Biological Psychiatry
Verified
Journal Article
Open access
SKSiegfried Kasper
Siegfried Kasper
WCWiesław J. Cubała
Wiesław J. Cubała
AFAndrea Fagiolini
Andrea Fagiolini
JRJosep A. Ramos-Quiroga
Josep A. Ramos-Quiroga
DSDaniel Souery
Daniel Souery
Allan YoungAllan Young
Allan Young
Despite the available therapies for treatment-resistant depression (TRD), there are a limited number that are evidence-based and effective in this hard-to-treat population. Esketamine nasal spray, ...

20 February 2015 in Psychological Medicine
Verified
Journal Article
Open access
PDF file
PFPanagiotis Ferentinos
Panagiotis Ferentinos
AKA. Koukounari
A. Koukounari
RPR. Power
R. Power
MRMargarita Rivera
Margarita Rivera
RUR. Uher
R. Uher
CLCathryn Lewis
Cathryn Lewis
Background: Strategies to dissect phenotypic and genetic heterogeneity of major depressive disorder (MDD) have mainly relied on subphenotypes, such as age at onset (AAO) and recurrence/episodicity. Yet, evidence on whether these subphenotypes are familial or heritable is scarce. The aims of this study are to investigate the familiality of AAO and episode frequency in MDD and to assess the proportion of their variance explained by common single nucleotide polymorphisms (SNP heritability).Method: For investigating familiality, we used 691 families with 2–5 full siblings with recurrent MDD from the DeNt study. We fitted (square root) AAO and episode count in a linear and a negative binomial mixed model, respectively, with family as random effect and adjusting for sex, age and center. The strength of familiality was assessed with intraclass correlation coefficients (ICC). For estimating SNP heritabilities, we used 3468 unrelated MDD cases from the RADIANT and GSK Munich studies. After similarly adjusting for covariates, derived residuals were used with the GREML method in GCTA (genome-wide complex trait analysis) software.Results: Significant familial clustering was found for both AAO (ICC = 0.28) and episodicity (ICC = 0.07). We calculated from respective ICC estimates the maximal additive heritability of AAO (0.56) and episodicity (0.15). SNP heritability of AAO was 0.17 (p = 0.04); analysis was underpowered for calculating SNP heritability of episodicity.Conclusions: AAO and episodicity aggregate in families to a moderate and small degree, respectively. AAO is under stronger additive genetic control than episodicity. Larger samples are needed to calculate the SNP heritability of episodicity. The described statistical framework could be useful in future analyses.

11 November 2022 in The World Journal of Biological Psychiatry
Verified
Journal Article
Closed access
FPFabio Panariello
Fabio Panariello
SKSiegfried Kasper
Siegfried Kasper
JZJoseph Zohar
Joseph Zohar
DSDaniel Souery
Daniel Souery
SMStuart Montgomery
Stuart Montgomery
CFChiara Fabbri
Chiara Fabbri
Objectives. This study aimed to identify factors associated with side effects of psychotropic drugs in a real-world setting enriched with treatment-resistant depression patients. Methods. A total of 1410 depressed patients were treated in a naturalistic setting. Side effects were measured with the Udvalg for Kliniske Undersogelser Side Effect Rating Scale (UKU); the total score and UKU subscales were considered. Clinical-demographic variables were tested for association with side effects in univariate and then multivariate analyses. Results. Total, psychic, and neurological side effects were associated with depressive symptom severity, while autonomic side effects were higher in those with somatic comorbidities and other side effects were lower in patients receiving trazodone. In multivariate analyses, depressive symptom severity was associated with psychic and total side effects, while generalized anxiety disorder with neurological side effects and somatic comorbidities remained associated with autonomic side effects. Trazodone was associated with lower side effects and with augmentation treatments. Augmentation therapies showed opposite effects depending on response status, i.e., increased or decreased the risk of side effects in responders and non-responders/resistant patients, respectively. Conclusions. Psychic side effects may be difficult to distinguish from depressive symptoms and factors associated with different types of side effects are heterogeneous and likely interacting.

12 October 2021 in International Journal of Neuropsychopharmacology
Verified
Journal Article
Open access
Lucie BartovaLucie Bartova
Lucie Bartova
GFGernot Fugger
Gernot Fugger
MDMarkus Dold
Markus Dold
Alexander KautzkyAlexander Kautzky
Alexander Kautzky
MSMarleen Margret Mignon Swoboda
Marleen Margret Mignon Swoboda
SKSiegfried Kasper
Siegfried Kasper
Background: Augmentation with second-generation antipsychotics (SGAs) represents an evidence-based psychopharmacotherapeutic strategy recommended in case of insufficient response to the first-line antidepressant (AD) treatment in major depressive disorder (MDD). Comparative evidence regarding efficacy and prescription preferences of the individual SGAs is scarce. Methods: In the scope of this European, multi-site, naturalistic cross-sectional investigation with retrospective assessment of treatment outcome, we compared sociodemographic and clinical characteristics of 187 MDD patients receiving either quetiapine (n = 150) or aripiprazole (n = 37) as augmentation of their first-line AD psychopharmacotherapy. Results: Comorbid posttraumatic stress disorder and diabetes were significantly associated with aripiprazole augmentation in our primary and post-hoc binary logistic regression analyses. Furthermore, we identified an association between aripiprazole co-administration and the presence of additional psychotic features, higher rates of AD combination treatment, and a longer duration of psychiatric hospitalizations during the lifetime, which, however, lost significance after correcting for multiple comparisons. Regarding treatment outcome, we found a trend of higher response rates and greater reductions in severity of depressive symptoms in MDD patients dispensed quetiapine. Conclusions: Factors associated with a more chronic and severe profile of MDD seem to encourage clinicians to choose aripiprazole over quetiapine, that was, however, administered in the majority of our MDD patients, which might reflect the current approval situation allowing to prescribe exclusively quetiapine as on-label augmentation in MDD in Europe. Given the retrospective assessment of treatment response, the markedly smaller proportion of patients receiving aripiprazole augmentation generally showing an unfavorable disease profile, and the partially heterogeneous statistical robustness of our findings, further studies are required to elaborate on our observation and to generate unambiguous recommendations regarding the choice of first-line SGA augmentation in MDD.

28 February 2021 in Clinical Psychopharmacology and Neuroscience
Verified
Journal Article
Open access
PDF file
CCConcetta Crisafulli
Concetta Crisafulli
MCMarco Calabrò
Marco Calabrò
LMLaura Mandelli
Laura Mandelli
SWSheng-Min Wang
Sheng-Min Wang
SLSoo-Jung Lee
Soo-Jung Lee
ASAlessandro Serretti
Alessandro Serretti
Concetta Crisafulli*, Marco Calabrò*, Laura Mandelli, Sheng-Min Wang, Soo-Jung Lee, Changsu Han, Ashwin Patkar, Prakash Masand, Chi-Un Pae, Daniel Souery, Julien Mendlewicz, Alessandro Serretti. Clin Psychopharmacol Neurosci 2021;19:46-52. https://doi.org/10.9758/cpn.2021.19.1.46